Skip to main content
Clinical Trials/NL-OMON39966
NL-OMON39966
Recruiting
Not Applicable

Monitoring of hemodynamics in heart failure patients by intracardiac impedance measurement - Bio.Detect HFII

Biotronik0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Biotronik
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Biotronik

Eligibility Criteria

Inclusion Criteria

  • \* Patients with an indication for CRT\-D device implantation according to the opinion of the treating physician who were not implanted with a CRT\-device before (de novo CRT\-patients only).
  • \* Patients being implanted with single and dual chamber ICDs before may be included in the study.
  • \* Patients who are planned to be implanted with a BIOTRONIK Lumax740 HF\-T device (or successor).
  • \* Patients planned to be implanted with a bipolar LV\-lead with a minimum distance of 15 mm between tip and ring.
  • \* Patients implanted (or planned to be implanted) with a true bipolar RV\-lead.
  • \* Patients with NYHA class II and III (with both ischemic or non\-ischemic etiology or dilative cardiomyopathy as underlying disease)
  • \* Patient is willing and able to comply with the CIP and has provided written informed consent.
  • \* Patient accepts Home Monitoring concept and has sufficient GSM/GPRS net coverage.
  • \* Evaluable echocardiographic measurements.
  • \* Patients with LVEF \>\= 15% and \<\= 35%

Exclusion Criteria

  • \* Patients with diagnosed persistent or permanent atrial fibrillation.
  • \* Patients suffering from aortic valve stenosis or from more than a trace of aortic valve insufficiency patients with aortic valve prosthesis.
  • \* Heart surgery performed in the 3 months prior to enrollment or planned for the time of study participation.
  • \* PTCA expected within the first 3 months of study participation.
  • \* Post\-HTX or listed for HTX.
  • \* Non\-ambulatory patients.
  • \* Patients requiring chronic renal dialysis.
  • \* Life expectancy \< 1 year due to a noncardiac disease.
  • \* Patient age \< 18 years.
  • \* Patient is addicted to alcohol, medical drugs or illegal drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials